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Abstract 
Although the disease burden of Respiratory Syncytial Virus (RSV) is significant, no human 
vaccine exists. Historical clinical trial complications in the 1960s and the lack of understanding 
concerning RSV viral correlates of protection (CoP) and viable in vitro and in vivo models have 
delayed RSV vaccine development. The World Health Organization (WHO), PATH, the Bill & 
Melinda Gates Foundation, and the Respiratory Syncytial Virus Network have been dedicated to 
RSV research efforts. The new vaccine and monoclonal antibody (mAb) candidates, built upon 
emerging knowledge, show potential for human vaccine viability by 2025 according to the 
WHO’s Product Development for Vaccines Advisory Committee (Mazur et al., 2018; Shi et al., 
2017). This review will focus on challenging aspects of RSV vaccine development and aim to 
explore current vaccine approaches in clinical development to discuss which show potential for 
human vaccine viability. 
 
1. Introduction 
Human RSV is a negative-sense, enveloped, nonsegmented, single-stranded- RNA virus of the 
Paramyxoviridae family, genus Pneumovirus (Higgins, Trujillo, & Keech, 2016; Piedimonte & 
Perez, 2014). A major cause of respiratory disease in pediatric and elderly populations, the first 
episode of RSV infection commonly occurs early during the first two years of life and presents 
as an acute lower respiratory infection (ALRI) with congestion, cough, and possible upper 
respiratory nasal irritation (Mazur et al., 2018; Piedimonte & Perez, 2014; Piedimonte, 2015).  In 
high-risk RSV populations such as: young infants (0-6 months), older infants and young children 
(2 months and older), and older adults (65 years or older), severe lower respiratory infection 
(SLRI) can develop due to defects in the populations’ immune systems triggering bronchiolitis, 
pneumonia, and episodes of apnea (Mazur et al., 2018; Mohapatra & Lockey, 2008; Piedimonte, 
2015). RSV can also have long-term adverse effects on pediatric patients like impairment of 
learning and memory storage and potentiation of asthma throughout childhood following 
wheezing caused by RSV (Espinoza et al., 2013; Rezaee, Linfield, Harford & Piedimonte, 2017).  
 
Unfortunately, many complications exist with developing viable vaccine candidates. The 
pediatric assumed naïve and elderly weakened immune statuses complicate the understanding of 
which immune responses are necessary for complete RSV immunity. RSV naturally generates 
incomplete immunity, so subsequent infections are currently probable, despite the presence of 
significant antibody titers to immunogenic proteins (Piedimonte & Perez, 2014). Subsequent 
infection generally elicits mild upper respiratory infection (MURI) in immunocompetent 
populations with sneezing, coughing, and rhinorrhea (Higgins et al., 2016). The virus is passed 
between individuals via physical contact with respiratory secretions from the nasopharyngeal or 
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conjunctival mucosa of infected individuals. It has been shown that RSV can survive, “on hard 
surfaces for up to six hours, on rubber gloves for 90 minutes, and on skin for 20 minutes,” 
(Piedimonte & Perez, 2014). Air sampling data has shown that RSV is rarely detectable, and 
transmission via aerosolization is uncommon (Piedimonte & Perez, 2014). 
 
1.1 Disease Burden 
Globally it was estimated in 2015 that RSV was responsible for 28% of all ALRI episodes and 
13-22% of all ALRI mortalities in children less than five years old. These estimates, as shown in 
Figure 1., equate to an estimated 33·1 million episodes of RSV-ALRI and 118,200-149,400 
RSV-ALRI deaths in young children in 2015. Thirty million of these RSV-ALRI cases occurred 
in children in low-income and middle-income countries; however, these estimates may not 
reflect the complete RSV burden due to under-reporting of cases and deaths that may have 
occurred due to inadequate healthcare access, diagnostic capacity, and biologic handicaps (Shi et 
al., 2017; Geoghegan et al., 2017; Higgins et al., 2016).  Annually, in the United States, RSV is 
responsible for an estimated 125,000 pediatric hospitalizations and 250 infant deaths (Piedimonte 
& Perez, 2014). While RSV has a substantial effect on children, elderly populations also suffer 
as it is estimated that annually in the United States 11,000 elderly individuals die as a result of 
illnesses related to RSV infection. Elderly adults most at risk include those who are community-
dwelling, in long-term care, or who frequent adult day care settings. Other high-risk adult groups 
include immunocompromised patients and those with cardiopulmonary disease (Branche & 
Falsey, 2015; Falsey, Hennessey, Formica, Cox, & Walsh, 2005).  
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1.2 RSV Treatment 
Currently, there are no treatment options to cure RSV. Most RSV care is palliative, and focuses 
on opening distressed airways with supplemental oxygen and mechanical ventilation if necessary 
(Higgins et al., 2016). Proper hydration is paramount, so intravenous fluids have been utilized in 
hospital settings (Branche & Falsey, 2015). Hypertonic saline has also been used for hospitalized 
patients to improve mucociliary clearance (Piedimonte & Perez, 2014). Pharmacological agents 
like bronchodilators or corticosteroids have been used to relieve RSV symptoms, but efficacy has 
not been proven during randomized controlled trials (Higgins et al., 2016). In elderly populations 
with chronic lung disease inhaled and systemic corticosteroids are prescribed to relieve acute 
exacerbation associated with wheezing and bronchospasm (Branche & Falsey, 2015). This 
practice has not been supported for infants during the first year of life because of safety concerns 
regarding corticosteroids' effects on rapid lung growth during this developmental period 
(Piedimonte & Perez, 2014).  
 
Ribavirin, a synthetic nucleoside analog, has broad in vitro activity against many RNA and DNA 
viruses (Piedimonte & Perez, 2014). Approved for severe RSV infection therapy, it only 
provides a modest short-term improvement of respiratory infections. Once supported for routine 
use in 1993 by the American Academy of Pediatrics Committee on Infectious Diseases, the 
committee changed its recommendation for the use of Ribavirin to treat RSV in 1996 to “may be 
considered” (Rezaee et al., 2017). In immunocompetent patients, RSV infection is asymptomatic 
for the first three to five days post-infection. During those first days, the virus, “reproduces 
exponentially and reaches the lungs,” where it begins causing respiratory distress symptoms after 
five to seven days (Piedimonte, 2015). Administering Ribavirin at this point post-infection does 
not have a large effect on the already disappearing RSV viral load, and multiple randomized 
trials were not able to demonstrate any short- or long-term benefits (Piedimonte & Perez, 2014). 
Ribavirin’s use has since been restricted to patients with T cell immunodeficiency due to limited 
host defenses, prolonged hospitalization due to aerosol administration, risks for potential 
toxicity, and high cost (Rezaee et al., 2017). One passive immunity neutralizing mAb, 
Palivizumab, is available for RSV prevention in high-risk infants aged less than two years but 
lacks data for treatment in children or adults (Branche & Falsey, 2015). This study gap may be 
due to the tremendous financial burden multiple dosing studies would assume since Palivizumab 
can cost $8000 or more per dose (Higgins et al., 2016; Branche & Falsey, 2015). 
 
2. RSV Vaccine Development Difficulties to Overcome 
2.1 Historical Caution 
One of the most detrimental factors that has inhibited Human RSV vaccine development is the 
catastrophic vaccine failure of a formalin-inactivated (FI) RSV vaccine from 1966. During one 
study, 80% of infants given the vaccine developed severe bronchiolitis or pneumonia after wild-
type infection, compared to only 5% for the placebo group. Ultimately two of the vaccinated 
infants died (Kim et al., 1969). This disease response following vaccination caused alarm that 
other non-replicating RSV vaccines may cause RSV-naïve children to experience high titers of 
non-neutralizing antibodies and Th2, MHC II cellular processing that can lead to immune 
complex deposition, complement activation, and allergic inflammation. This harmful immune 
response became known as enhanced respiratory disease (ERD), and the specific etiology 
remains unknown (Higgins et al., 2016; Rezaee et al., 2017; Acosta, Caballero, & Polack, 2015). 
Current vaccine candidates must avoid inducing ERD to progress through development. 
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2.2 Protein Structure & Pathogenicity 
Another difficulty in developing a Human RSV vaccine has been establishing an understanding 
of the pathogenicity of different RSV proteins and their abilities to elicit an immune response in 
order to establish CoP. Learning which protein structures elicit the strongest immunological 
memory will help inform future vaccine development. A and B strains exist and each consist of 
10 genes that encode 11 proteins as shown in Figure 2. The strains circulate alternatively every 
1-2 years, and it is thought that a more severe disease pattern may be characteristic of RSV strain 
A (Dudas & Karron, 1998; Lee & Chang, 2017). Two of the most important proteins that 
stimulate neutralizing antibodies are the F (fusion) and G (attachment) transmembrane surface 
proteins. G protein's amino acid sequence is not highly conserved, and this variation is what 
causes division between strains A and B. G protein only shares 53% similarity between strains 
(Lee & Chang, 2017). Little is also known about the surface structure of G protein, but based on 
its location within a host, G protein can change structure from, “an oligomer on the surface of 
RSV particles,” to a, “monomer when secreted from infected cells in soluble form” (Mazur et al., 
2018). The G protein monomer soluble form, “can act as a decoy that helps the virus to evade the 
host antibody response” (Mazur et al., 2018; Escribano-Romero et al., 2004; Bukreyev et al., 
2008). Although G protein induces a robust neutralizing antibody response, it is not commonly 
targeted for vaccine development due to antigenic and genetic variability (Mazur et al., 2018; 
Lee & Chang, 2017). 
 
The F protein is more commonly targeted than G protein during vaccine development due to its 
high conservation (90%) between A and B strains (Taleb et al., 2018).  It is also responsible for 
the syncytia for which RSV is named. Upon fusion of the host and vial plasma membranes, the F 
protein causes the aggregation of multinucleated cells allowing for transmission of the virus 
between host cells (Piedimonte & Perez, 2014). F protein exists in two variant conformations, 
Pre- and Post- F. Post-F had been isolated for many years, and in 2013 Pre-F was discovered in a 
metastable state. Under natural conditions, its viability lasts for a fraction of a second before 
turning into stable Post-F (Higgins et al., 2016; Taleb et al., 2018). The main differences between 
Figure 2.  RSV genome and proteins. a Map of negative-sense RNA genome where nt and aa indicate nucleotides and amino 
acid lengths, respectively. b Mapping of 11 proteins on RSV virion and their corresponding classes (Taleb, Asmaa, Khalid, & 
Hadi, 2018). 
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the F protein variants are the surface antigenic sites located on the protein. Both conformations 
share sites I, II, III, and IV, but Pre-F also presents sites Ø and V. Ø and V sites have shown high 
neutralizing activity, and Ø has shown in pre-clinical studies to, “elicit antibodies more potent 
than palivizumab” (Higgins et al., 2016; Mazur et al., 2018). Since the most neutralization-
sensitive sites are exclusive to the Pre-F conformation, many new vaccine candidates have 
targeted Pre-F. Shared sites II, III, and IV have also shown medium to high neutralization 
potential, but site III stimulates a stronger antibody response when isolated on the Pre-F 
conformation (Graham, 2017). Historically site II has been an important antigenic target due to 
its conservation between RSV strains A and B (Rezaee et al., 2017).  
 
Most of the RSV proteins have been explored as possible antigenic targets, but few apart from F 
and G are being utilized currently in vaccine development. The third transmembrane surface 
protein, SH, is small and hydrophobic with transmembrane and extracellular domains thought to 
possibly aid in fusion (Mohapatra & Lockey, 2008; Mazur et al., 2018; Rezaee et al., 2017). The 
extracellular domain has been shown to inhibit cell apoptosis via inhibition of the TNF-α 
pathway, and this action may prove essential for induction of antibody dependent cell-mediated 
cytotoxicity. Other non-membrane RSV proteins such as N, NS2, M2-1, M2-2, and M may be 
essential for vaccine development to induce potent T-cell responses. The M and N proteins are 
structural in their functions. M protein is associated with the viral membrane and gives virions 
their filamentous shape. N protein is responsible for encapsidation of the RNA genome. The 
other possible antigenic proteins are nonstructural and focus on viral function and survival. NS2 
inhibits the host interferon response and promotes epithelial cell shedding. M2-1 and M2-2 are 
specific to pneumoviridae viruses and are vital for viral transcription (Rezaee et al., 2017; Mazur 
et al., 2018).  
 
2.3 RSV Modeling 
Although much is being discovered concerning RSV protein pathogenicity, in vitro and in vivo 
models pose another difficulty in RSV vaccine development. In order to test preclinical vaccine 
candidates, models must be developed and utilized to assess the potential for ERD and vaccine 
immunity (Mazur et al., 2018). In vitro, RSV replicates in a wide range of cell lines from various 
tissues and hosts. The HEp-2 cell line is most commonly used to grow RSV. The purity of this 
cell line is unclear, so replication in this line may be less suitable for the production of virus used 
for vaccine applications. The cancerous nature and non-respiratory origin of several cell lines are 
limitations for RSV replication. Isolated human airway epithelial cells grown at an air-liquid 
interface have been used to adapt clinical RSV isolates to cell culture. The product cells contain, 
“pseudostratified, mucociliary airway epithelium that displays similar morphologic and 
phenotypic characteristics of the in vivo human cartilaginous airway epithelium” (Heylen, Neyts, 
& Jochmans, 2017). 
 
In vivo animal models present an additional challenge. Viruses like bovine RSV and ovine RSV 
have been identified in their respective species to model disease pathology and immune 
responses that are similar to human RSV infections in children (Heylen et al., 2017). Researchers 
have been able to utilize these models to understand the pathology and mechanisms of immunity 
towards pneumovirus infections. This has helped serve as a way to evaluate human RSV vaccine 
concepts during pre-clinical development (Taylor, 2017). Although beneficial, these models are 
genetically different from human RSV. Neonatal lambs have been challenged with Human RSV 
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and have shown successful disease replication. The similarity of size and organization of airway 
and lymphoid tissue make this model attractive, but lack of antibodies and genetic sequencing 
tools along with the complexity of population maintenance, are pitfalls of human RSV modeling 
in sheep (Bem, Domachowske, & Rosenberg, 2011). 
 
Other non-human primates and small animal mammalian models have also been explored. 
Chimpanzees are currently the only non-human primate model that is permissive to human RSV 
replication and infection. ARLI and SRLI have not been induced in this model, but MURI has 
been monitored in chimpanzees. The genetic similarity and size of chimpanzees make then 
attractive models, but the ethical burden and economic resources required for the logistical 
maintenance of small chimpanzee populations inhibits this model’s use (Bem et al., 2011; 
Taylor, 2017). Other non-human primates like African green monkeys, three species of 
macaques (rhesus, cynomolgus, and bonnet monkeys), owl monkeys, Cebus monkeys, and 
baboons have been explored as models for human RSV with varying benefits and limitations. 
Unlike chimpanzees these non-human primate species are semi-permissive to human RSV 
replication, so their viral replication responses were comparatively moderate to low to inoculum 
levels. Often clinical signs of disease did not develop or were limited to MURI symptoms. 
Pathology studies were not done on all species models, but those reported showed signs of 
broncho-interstitial pneumonia, alveolitis, and syncytium of cells. Vaccine-enhanced pathology 
has been studied in African green monkeys and macaque species, but limited vaccine-enhanced 
pathology has been explored in the other non-human primate species discussed (Taylor, 2017).  
 
Small animal mammalian models mostly consist of rodent species including mice, rats, and to 
lesser degrees ferrets, guinea pigs, Syrian hamsters, and chinchillas (Taylor, 2017). The BALB/c 
mouse has been the most common animal model for experimental human RSV disease (Bem et 
al., 2011). This mouse model is semi-permissive and shows intermediate susceptibility to human 
RSV infection. A high, >106 plaque-forming units (PFU), dose of human RSV is required to 
produce clinical signs of disease. Unlike clinical signs in humans that focus on ARLI, SRLI, or 
MURI, BALB/c mouse disease induced by human RSV is measured as weight loss, ruffled fur, 
and hunched posture. Pathological sectioning of airways must be done to measure the pulmonary 
manifestation of human RSV with studies showing mild to moderate bronchiolitis has been 
induced (Taylor, 2017). The convenience provided by the vast amount of genetic knowledge and 
mouse-specific reagents and molecular tools makes this model attractive. However, the innate 
and adaptive immune response stimulated in BALB/c mice differs significantly from humans and 
does not provide sufficient antigenic modeling of human disease. The anatomy and size of mice 
lungs also differ significantly due to fewer bronchioles and less complex airway branching and 
complicates disease monitoring when compared to humans (Bem et al., 2011). 
 
An alternate rodent model, the cotton rat, has proven to be a superior model. Although semi-
permissive, this rat model requires a 104 PFU dose of human RSV to induce ALRI while peak 
replication levels are nearly 100 fold higher than in mouse models (Heylen et al., 2017). Both 
URI and LRI have been monitored in cotton rat models, and clearance of the virus follows a 
similar timeline as in humans with clearance happening by day seven post-infection. Pathologic 
sectioning of the airways has shown mild to proliferative bronchiolitis, sloughed epithelial cells, 
and patchy atelectasis (Taylor, 2017; Bem et al., 2011). The cotton rat model has become widely 
used to evaluate the efficacy of vaccines, antivirals, and neutralizing antibodies like palivizumab 
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(Bem et al., 2011). It has also been used to model alveolitis after FI human RSV vaccination, as a 
model for ERD. Although these uses are productive, the extrapolation of vaccine results from 
this model to show safety in higher mammals should be done with discretion as complete 
protection stimulated against human RSV in the cotton rat model has failed to show the same 
efficacy in African green monkeys (Taylor, 2017). Cotton rat care also adds an added difficulty 
due to their fragile and easily agitated nature. Specialized training is required for their care and 
handling, but specific immunological reagents are being developed to advance the usage of this 
model (Bem et al., 2011).  
 
2.4 Correlates of Protection 
Due to the heterogeneity of the RSV protein landscape and models utilized for vaccine 
development, the CoP against RSV infection and disease have been difficult to determine. As 
researchers develop new vaccine approaches, the endpoints of their studies vary based on 
multiple regulatory points. The sizeable historical use of mAbs to protect high-risk patients via 
passive immunity has established a plethora of data concerning correlations between neutralizing 
antibodies and disease prevention and could act as a cornerstone for establishing RSV correlates 
of prevention from disease. This type of passive immunity has been analyzed in maternal sera, 
cord blood, infant sera, and by passive antibody transfer studies (Kulkarni, Hurwitz, Simões, & 
Piedra, 2018; Jorquera, Oakley, & Tripp, 2013).  
 
Due to the nature of humoral immunity, there may be many inhibitory mechanisms responsible 
for antigenic neutralization of RSV (Kulkarni et al., 2018). RSV-specific nasal IgA, a component 
of mucosal antigenic memory, may be useful for establishing CoP for infection. One study has 
shown that IgA more strongly correlates with protection compared to measurements of serum 
neutralizing antibody in adults (Habibi et al., 2015). This highlights the importance mucosal 
immunity may play in RSV protection. The Habibi et al. (2015) study also showed rapidly 
waning IgA levels caused individuals to be susceptible to RSV reinfection within months. Upon 
reinfection, IgA memory B cells were not significantly mobilized and suggested a hardship 
vaccine development will need to overcome through dosage and administration strategies or 
stimulation of enhanced immunologic memory. 
 
Antibodies targeted towards specific RSV proteins, as previously discussed, may offer systemic 
immunity. Neutralizing assays will need to be developed in response to the specificity of vaccine 
antibody type, but no standardization or threshold exists despite the frequent use of neutralizing 
activity of serum as an endpoint for vaccine trials. An ELISA to neutralization response ratio 
representing the, “ratio of times-increase in RSV-binding antibodies to times-increase in RSV-
neutralizing antibodies,” of less than one may be a significant correlate of protection (Mazur et 
al., 2018). Other definitive CoP may be vaccine-type specific. Times-rise in antibody titer could 
be an indicator of B-cell priming, relevant for live-attenuated vaccines (Mazur et al., 2018). This 
vaccine type is targeted towards the naïve pediatric immune system because it generates 
replication of high amounts of antigenic non-virulent material that stimulates a natural host 
immune system response.  
 
Standardization of neutralizing assays is a considerable feat, and a recent PATH, WHO, and the 
National Institute for Biological Standards and Control (NIBSC) exercise examined 12 different 
neutralizing assays in order to establish standardized neutralizing antibody titers (Kulkarni et al., 
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2018). This regulatory effort led to a new RSV International Standard Antiserum with 1000 IU 
of RSV subtype A neutralizing activity per vial available through NIBSC (Mazur et al., 2018). 
Further standardization of other immunological assays will need to be developed in the future. 
 
Besides humoral immunity, T cell-mediated immune responses could act as a CoP. In cases of 
LRI, CD8 T cells are essential for viral clearance, and as discussed with the FI vaccine candidate 
from 1966, Th2, MHC II- biased immune responses are indicative of ERD across human and 
animal models of disease (Graham, 2017; Mazur et al., 2018). Kulkarni et al. (2018) suggest that, 
“neutralizing antibodies will likely serve as a CoP in infants and young children but in older 
adults, a CoP associated with virus clearance might be a better target.” Despite this 
recommendation, measurements of Th1 and Th2 responses have been used as safety measures 
for most RSV vaccine platforms due to their relationship with ERD in children. High levels of 
Th2 are indicative that ERD may be induced, and high levels of Th1 are indicative of an 
appropriate immune response in vulnerable populations. These indications only further support 
that establishing CoP will vary depending on vaccine study, target age, and host immune factors 
(Mazur et al., 2018; Kulkarni et al., 2018).  
 
3. RSV Vaccine and mAb Candidates 
3.1 Historical Perspective 
Many variables affect vaccine development as discussed previously. New knowledge and 
vaccine failures help further RSV vaccine development, and PATH creates a monthly RSV 
Vaccine and mAb Snapshot to organize current RSV vaccine efforts. For four decades only live-
attenuated vaccines were tested for active infant immunization due to fear of ERD, but due to the 
overwhelming necessity for an RSV vaccine globally, RSV vaccine development has increased, 
and other vaccine types have been explored (Higgins et al., 2016). In December 2015, 60 vaccine 
and mAb candidates were in varying stages of development and represented six broad vaccine 
platforms and one immune-prophylaxis platform. In October 2018, 45 vaccine and mAb 
candidates were in varying stages of development, and this change represents failures and 
advancements through different stages of clinical development. As shown in Table 1., 31 of the 
vaccine and mAb candidates are shared between December 2015 and October 2018 PATH 
Snapshots. In the following section, examples representing the various vaccine platforms will be 
discussed.  
 
Vaccines are targeted for use in three populations: pediatric, elderly, and maternal. Pediatric and 
elderly populations are targeted due to their severe and immense disease burden. Pregnant 
women have been targeted as potential RSV vaccine recipients due to the passive immunity they 
afford their children during utero and possible breastfeeding after birth (Blanco et al., 2017). 
Development of vaccines requires multiple resources, and this continuation of candidate 
development shows the potential vaccine candidates must have before entering clinical 
development and trials.  
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3.2 Live Attenuated/ Chimeric Vaccine Candidates  
Current live-attenuated vaccines have focused on genetically altering RSV genes to achieve 
attenuation. Traditional vaccine attenuation techniques like the passage in sub-optimal 
replication cell types or temperatures have historically failed RSV development (Karron et al., 
2015). The balance of achieving high levels of attenuation while preserving immunogenicity is 
the inherent challenge for this vaccine type, and through the advancements in RSV protein 
knowledge, researchers have been able to utilize modern reverse genetic systems to target and 
alter RSV proteins to achieve attenuation (Collins & Melero, 2011). This approach allows 
researchers more attenuation stability than relying on mutagen strains. This approach is primarily 
targeted towards infant populations due to their assumed RSV-naïve status. Live-attenuated 
vaccines generally elicit humoral and cell-mediated immune responses, and a study of seven 
live-attenuated vaccine candidates in seronegative children showed safe profiles for children as 
young as one month old (Wright et al., 2007). Currently, four live-attenuated vaccines are in 
phase one of clinical trials. Popular alterations include deletion or substitution of the M2-2, NS2, 
or G proteins.  
 
Two chimeric vaccines are in clinical trials and focus on delivering RSV protein genetic material 
as antigens. The Sendai Virus (SeV) is a modified mouse parainfluenza virus similar to human 
parainfluenza virus type 1 (Jones et al., 2014). The SIIPL, St. Jude Hospital SeV/RSV candidate 
currently in phase one utilizes the SeV virus to deliver RSV F protein genetic material to the 
vaccine recipient. In pre-clinical pediatric cotton rat model studies, this vaccine candidate was 
Table 1. PATH 
RSV Vaccine and 
mAb Snapshot 
October 2018. 
(PATH, 2018) 
 
Highlighting represents 
shared candidates between 
the December 2015 PATH 
Snapshot and updated 
version (PATH, 2015). 
Blue highlighting 
represents vaccines that 
remain in the same phase 
of development between 
snapshots, and red shows 
movement through 
clinical development. 
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able to elicit immune responses that were protective in the presence of simulated maternal 
antibody titers (Jones et al., 2014). The current phase one clinical trial (NCT03473002) will 
enroll up to 25 healthy participants to test the vaccine's safety, prolonged detectability, and 
immune response via ELISA (NIAID, 2018).  
 
Another chimeric vaccine approach, Pontificia Universidad Catolica de Chile BCG/RSV, utilizes 
the tuberculosis BCG vaccine as a vector for the RSV N protein gene (Rey-Jurado, Soto, Gálvez, 
Kalgeris, 2017). Utilization of the BCG vaccine, already approved for newborns, to additionally 
induce RSV immunity, would provide newborns dual immunity to both respiratory diseases. The 
BCG vaccine has been shown to elicit a Th1 immune response, and pre-clinical data suggests the 
BCG/RSV vaccine promotes a protective T cell immune response via the recruitment of Th1 
cells (Bueno et al., 2008; Cautivo et al., 2010). The phase one clinical trial (NCT03213405) is 
currently recruiting 24 males, aged 18-50 years old, to test three dosages of the BCG/RSV 
vaccine candidate against a conventional BCG dose (Pontificia Universidad Catolica de Chile, 
2017). 
 
3.3 Subunit Vaccine Candidates 
Another broad vaccine platform being explored is the subunit vaccine type. This vaccine type is 
targeted towards elderly and maternal populations. Due to previous episodes of ERD elicited in 
animal models following subunit vaccination, this vaccine platform is unsuitable for infant 
populations (Murphy et al., 1990; Connors et al., 1992). Subunit vaccines utilize specific purified 
viral proteins often paired with an adjuvant to elicit immunity. There are currently five vaccine 
candidates in phase one of clinical trials and one candidate in phase two. Four of the candidates 
utilize the F protein as their antigenic material.  
 
One recent late phase vaccine failure in 2016, MEDI-7510 (NCT02508194), a subunit vaccine 
candidate utilizing a Post-F conformation as its antigenic material, was thought to have failed 
because the antibodies generated in response lacked appropriate epitope specificity when 
induced by Post-F (Langley, 2017; Mazur et al., 2018). The majority of current vaccine 
candidates utilizing F are specified as the Pre-F conformation. The study was also thought to 
have failed due to the study population, 1900 adults aged 60 or older at varying RSV risk levels, 
not having a high enough incidence of laboratory-confirmed RSV infection to confirm or deny 
study endpoints (Mazur et al., 2018).  
 
The phase two vaccine candidate, Pfizer RSV F Protein (NCT03572062), was recently 
suspended on October 10, 2018, during the enrollment period of nearly 474 healthy 60-85-year-
old participants. An amendment is pending, but the original protocol was set to study the safety, 
tolerability, and immunogenicity of six vaccine candidate formulations administered alone or 
alongside seasonal inactivated influenza vaccine (Pfizer, 2018).  
 
A novel subunit approach, Immunovaccine, VIB DPX-RSV-SH Protein (NCT02472548), has 
completed phase 1 trials. This vaccine candidate is a depot formulation utilizing the SH protein 
as its antigenic material. Forty healthy study participants aged 50-64 years old sustained 
measurable antigen-specific antibody levels and showed safe vaccine profiles despite pain 
complaints (Langley et al., 2018).  
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3.4 Recombinant Vaccine Candidates 
The third major broad vaccine platform, recombinant vaccines, has the highest number of 
vaccine candidates in phase two of clinical trials. The majority of current RSV recombinant 
vaccine development has focused on using adenovirus as the attenuated viral vector for specific 
RSV genes. One of the recombinant adenovirus vaccine candidates, GlaxoSmithKline 
Adenovirus, includes genes for F, N, and M2-1 proteins as RSV antigenic material. When 
studied during phase one clinical trial (NCT02491463), 72 healthy adults’ (mean age 30 years 
old) main complaints following vaccination during the first 0-6 days included general pain and 
fatigue. Blood work collected at time points 1, 3, 7, 30, 31, 33, 60, 180, 360 days post-
vaccination did not show significant abnormalities to suggest adverse vaccine reactions 
(GlaxoSmithKline, 2015). This study has since progressed to phase two (NCT02927873) where 
safety, reactogenicity, and immunogenicity will be monitored in infants aged 12-23 months 
(GlaxoSmithKline, 2016).  
 
Another recombinant adenovirus RSV vaccine candidate, Janssen Pharmaceutical Adenovirus, is 
currently being tested during phase two clinical trials (NCT03339713) for efficacy in pediatric 
and elderly populations. This vaccine uses the gene for the Pre-F conformation as antigenic 
material. The phase two clinical trial focused on elderly populations (>60-year-old) recently 
finished and aimed to discern if administration of the vaccine candidate paired with seasonal 
inactivated influenza vaccine was advantageous compared to seasonal influenza vaccination 
alone (Janssen Vaccines & Prevention B.V.a, 2017). Study results have yet to be released for the 
elderly study, but the phase two clinical trial (NCT03303625) for the pediatric targeted version 
of the Janssen Pharmaceutical Adenovirus vaccine candidate is currently vaccinating 60 
participants in two age ranges: healthy adults 18-50 years old and RSV-seropositive toddlers 12-
24 months old (Janssen Vaccines & Prevention B.V.b, 2017).  
 
The other recombinant RSV vaccine candidate, Bavarian Nordic MVA, uses modified vaccine 
Ankara (MVA) a live-attenuated poxvirus derivative as its recombinant vector. This RSV 
recombinant vaccine candidate utilizes genes for F, G (both RSV subtypes), N, and M2 proteins 
as its antigenic material (Mazur et al., 2018).  Phase two interim (NCT02873286) results show 
the vaccine candidate is well tolerated and induces humoral and T cell responses in older adults 
after a single vaccination. Planning has begun for the design of a phase three study (Bavarian 
Nordic, 2018). 
 
3.5 Particle-Based Vaccine Candidates  
The next relevant vaccine platform is particle-based vaccines. Novavax is a leader in this vaccine 
platform and utilizes a Sf9/insect baculovirus nanoparticle system to deliver antigenic particles 
of various diseases (Smith et al., 2012). The Novavax RSV F particle vaccine candidates, derived 
from infecting the ovary cells of fall armyworm insects with baculovirus engineered to generate 
recombinant Post-F protein, utilize their vector system to present Post-F protein conformation as 
an antigenic multimeric micelle similar in size to wild-type RSV within a host (Novavax, n.d.).  
 
This approach has been used to target maternal, elderly, and pediatric populations. The maternal 
formulation is in a phase three clinical trial (NCT02624947), and the pediatric formulation is in 
phase one (NCT02296463). The elderly formulation had advanced to a phase three clinical trial 
(NCT02608502) and was found to be safe, but the vaccine failed to meet efficacious study 
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endpoints defined as percentages of subjects that developed moderate-severe RSV-LRI and 
RSV-acute respiratory disease during the 2015-2016 RSV season following administration of 
placebo and vaccine candidate treatments (Novavax, 2015; Novavax, 2016). Novavax claimed 
that the failure was due to a low attack rate of RSV during the season they monitored and failure 
was not due to data acquisition or the drug product itself (Novavax, 2016). According to Mazur 
et al., “Another proposed explanation for failure of this vaccine candidate is that the quantity of 
the immune response to vaccination might not represent effective immunity.” Mazur et al. also 
noted that this failure suggests that late-phase clinical research should be conducted over 
multiple RSV seasons to prove efficacy. The trial has since been rolled over to phase two clinical 
trials (NCT03026348) where previously enrolled phase three participants were re-blinded and 
randomized between vaccine and placebo groups for a second round of vaccine administration 
(Novavax, 2016).  
 
3.7 mAb Candidates 
The other broad type highlighted on the PATH Snapshot is the immune-prophylaxis/combination 
platform focused on developing mAb for passive immunity. Palivizumab is approved in this 
category, but another mAb candidate, Medimmune, Sanofi Anti-F mAb, is currently in phase 
two of clinical trials and has shown immense promise. This mAb targets the Ø site on the Pre-F 
protein conformation of RSV, which has shown to be more neutralizing than the site II Post-F 
protein palivizumab targets (Robbie et al., 2013). The formulation of this mAb extends its half-
life three-fold, and one administration would remain viable throughout a complete RSV season. 
Palivizumab has provided passive immunity for many years, but the mAb’s financial burden has 
limited its use and relief. Pharmaceutical companies MedImmune and Sanofi have joined during 
the development of this prophylaxis tool and indicated that pricing would emulate vaccine 
markets (Mazur et al., 2018). If attained, this could provide reliable passive immunity for many 
who struggled before with RSV.  
 
4. Conclusion 
RSV vaccine development has expanded in response to the significant global disease burden. 
Although the FI vaccine failure of 1966 hindered vaccine development, progress has been made 
towards achieving a viable human RSV vaccine. As the understanding of the structure and 
pathogenicity of RSV proteins is enhanced, vaccine developers can narrow their target genetic 
material to more adequately stimulate a protective immune response balancing humoral and 
cellular immunity. Once these targets are further developed, the RSV vaccine field will need to 
continue to grow the understanding of in vitro and in vivo models to adequately test developing 
RSV vaccines. CoP can then be established to act as a standard for future RSV vaccine 
development. Current vaccine progress and failures that result during clinical trials help broaden 
the scientific understanding of immunity against RSV, and many candidates currently in 
development have shown promising results.  
 
Although there is a significant amount of information that evades developers today, emerging 
knowledge and innovation will improve current points of development and allow researchers to 
maximize the effectiveness of their vaccine candidates. Moving forward, it appears based on the 
understanding of protein structure and pathogenicity that the RSV vaccine development field is 
moving towards targeting the F surface protein opposed to the G surface protein. While G 
protein may elicit a strong antibody response, this change is supported by superior F protein 
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conservation between RSV strains. Specificity for the F protein has also emerged with the Pre-F 
conformation being targeted opposed to the widely used Post-F conformation. This shift should 
elicit new information and has been supported through the success of recent Pre-F conformation 
targeted candidates in the vaccine PATH Snapshot. Although specificity for RSV proteins has 
recently developed, the population scope of vaccine candidates is still targeted towards the most 
vulnerable populations— pediatric and elderly. Due to the complications associated with the 
pediatric naïve or elderly weakened immune systems, these populations need vaccines targeted 
towards eliciting immune responses appropriate for their population’s needs. Defining CoP in the 
future will help standardize the immune responses necessary for generating complete immunity 
in these populations and may range between antibody neutralizing effects and T cell recruitment. 
After a vaccine is developed and CoP established, other delivery modes should be compared 
across all vaccine platforms and populations. Administration time point regimens and dosages 
will also need to be established across all populations in response to the difficulty generated by 
waning RSV immunity after infection. Currently, these futuristic points of exploration remain 
second to developing a viable vaccine. The history of RSV vaccine development is vast; 
however, due to current advancements, a viable human RSV vaccine appears to be on the 
horizon.  
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